Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Learning objectives
- Phases of xenobiotic metabolism
- Phase II biotransformation enzymes
- Major conjugating (phase II) enzyme families
- Codeine metabolism is mix of phase I and II
- Glucuronidation
- The glucuronidation reaction
- UDPGA
- Biosynthesis of UDPGA
- Discovery of UDPGA
- UGTs are located in the endoplasmic reticulum
- Latency of UGTs
- The UGT family
- UGT polymorphisms
- UGT induction and inhibition
- The UGT1A gene
- Substrates for UGTs
- Probe substrates for selected UGTs
- Case study – bilirubin
- Bilirubin glucuronidation
- Genetics of bilirubin glucuronidation
- Crigler-Najjar syndrome type I
- Crigler-Najjar syndrome type II
- Gilbert’s syndrome (GS)
- Role of GS in adverse drug reactions
- Irinotecan and UGT1A1
- Irinotecan metabolism
- Irinotecan in Gilbert’s syndrome
- Atazanavir and UGT1A1 (1)
- Atazanavir and UGT1A1 (2)
- Positive effects of bilirubin/Gilbert’s syndrome
- Gilbert’s syndrome and cardiovascular disease
- Toxicology of acetaminophen (paracetamol)
- History of acetaminophen (paracetamol) (1)
- History of acetaminophen (paracetamol) (2)
- Clinical uses
- Acetaminophen therapeutic doses
- Acetaminophen metabolism in adults
- Acetaminophen toxicology
- Age-related differences in acetaminophen
- Differences between children & adults
- Acetaminophen metabolism during development
- Treatment for acetaminophen overdose
- Summary – UGTs
- Thank you
Topics Covered
- UDP-gucuronosyl transferases (UGTs)
- Glucuronidation
- UGT enzymes and their activities
- Co-substrate for UGTs
- UGT family
- Bilirubin metabolism
- Genetic diseases/syndromes associated with UGT1A1
- UGT1A1 in adverse drug reactions
Talk Citation
Collier, A. (2024, June 30). UDP-glucuronosyltransferases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 23, 2024, from https://doi.org/10.69645/KLPJ7282.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Abby Collier has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome. My name is
Abby Collier and this
lecture is about
UDP glucuronosyltransferases
and they are
an enzyme set that I
will be referring to
as UGTs throughout the talk.
0:14
The learning objectives
for this lecture
are to understand the
role of glucuronidation
which is the reaction
performed by
the UGTs in the metabolism
of endogenous compounds
in the body as well as
antibiotics which are compounds
from outside of the human body.
We want you to learn about
the co-substrates of
UGTs and their reactions
and where they
take place in the cell
and in the human body and
understand the complexity
of the UGT enzyme family.
This includes learning
probe substrates as well as
bilirubin metabolism in
the human body so that you
understand genetic diseases
and syndromes associated
with these enzymes and
their roles in adverse
drug reactions.
0:57
This picture shows the
phases of what we call
xenobiotic metabolism
and an example
is using the drug phenytoin.
From the top of the slide
you can see phenytoin undergoing
a Phase I metabolism
reaction which is
primarily reduction and
oxidation and then from
the metabolite
4-hydroxphenytoin through
a Phase II metabolism reaction
performed by the UGTs
to a glucurinide.
On the right hand
side in orange,
you can see how
phenytoin goes from
a very lipophilic drug to
a slightly water
soluble metabolite to
a highly water soluble
metabolite through
Phase II and this
enables excretion.
1:39
The Phase II biotransformation
enzymes also called
conjugating enzymes
are transferases
that primarily detoxify
the human body.
They are also found in other
animals insects and plants.
The reaction products
performed with
conjugation are far more soluble
and are usually
excreted by kidneys in
the urine or sometimes
in the bile.
These Phase II enzymes are what
we call bi-substrate enzymes.
They work on the
molecule of interest.
But they also use a
secondary molecule
to transfer motese from.
The enzyme reaction is to
transfer a component of the
co-substrate or all of it to
the substrate and
second from the bottom,
you'll see an example
of phenyl plus UDPGA,
which is the co factor
or the bi-substrate for
the UGT enzyme becoming
phenyl glucurinide plus UDP.
Although many phase
two enzymes work
on metabolites as shown
in the previous slide,
they can also work directly
on the drug chemical or
compound of interest.